Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

OBJECTIVE To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR ( ERBB1 ) and HER2 inhibitor, using prospective data collected in 44 clinical studies. PATIENTS AND METHODS Lapatinib (as monotherapy or in combination) was administered to 3689 patients in studies conduc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Mayo Clinic proceedings 2008-06, Vol.83 (6), p.679-686
Hauptverfasser:	Perez, Edith A., MD, Koehler, Maria, MD, PhD, Byrne, Julie, PhD, Preston, Alaknanda J., PhD, Rappold, Erica, BSN, Ewer, Michael S., MD, JD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Clinical Trials as Topic Female Heart Failure - chemically induced Humans Internal Medicine Male Middle Aged Neoplasms - drug therapy Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Quinazolines - adverse effects Quinazolines - therapeutic use Stroke Volume - drug effects Ventricular Dysfunction, Left - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!